|Bid||11.84 x 0|
|Ask||11.90 x 0|
|Day's Range||11.65 - 12.24|
|52 Week Range||2.65 - 15.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.10|
Aurora Cannabis to Host Fourth Quarter 2018 Investor Conference Call on September 25, 2018
CORAL GABLES, FL / ACCESSWIRE / September 21, 2018 / Marijuana stocks have remained on a high during the month of September and pre market trading has a number of these cannabis stocks heading higher. Traders have flocked to medical-marijuana producers like Tilray (TLRY), for instance, after the company won approval from the Drug Enforcement Administration to import a cannabis product drug into the U.S. for a clinical trial. With this being the case, there are multiple cannabis companies to look at as the October date in Canada comes closer.
Cannabis Legalization: Will the US Follow Canada's Lead? The cannabis market potential in the US is perhaps the most appealing of all to cannabis companies. Aurora Cannabis (ACB) (ACBFF) in its April 2018 investor presentation showed that the estimated market potential for medical cannabis in the US exceeded the markets in 15 countries where medical cannabis laws were pending approval at the federal level.
Cannabis Legalization: Will the US Follow Canada's Lead? The cannabis sector (HMMJ) in Canada has elicited hopes that the US may also move towards legalizing cannabis at some point. Currently, cannabis is still not legal at the federal level, but some states have ruled to legalize cannabis for medical purposes, while some states have legalized recreational use as well.
Canadian medical marijuana company Aleafia Health Inc. has been added to the Horizons Marijuana Life Sciences exchange-traded fund , the company said Friday. HMMJ is the first and biggest ETF offering exposure to the North American cannabis market with holdings that include Canadian players Aurora Cannabis Inc. and Canopy Growth Corp. . The ETF has gained 37% in 2018 as excitement builds ahead of Canada fully legalizing cannabis on Oct. 17. Aleafia is expecting to reach growing capacity of 38,000 kg of cannabis flower in 2019. The company has 50,000 individual patients using medical marijuana and on Thursday announced a partnership with Cronos Group Corp. on a study of the substance as a treatment for insomnia. Shares have gained 193% in 2018, while the S&P 500 has gained 9.6%.
In the earlier part of this series, we looked at cannabis companies’ median EV-to-sales (enterprise value-to-sales) multiple, which stood at 12.7x as of September 19. The median is based on the results of nine cannabis companies.
Cannabis stocks (HMMJ) have soared in recent weeks in anticipation of October 17, the date when recreational cannabis sales are slated to begin in Canada. Some of the stocks have grown exponentially, challenging the rationality of such movement. For example, Tilray (TLRY) has soared over 1,000% as of September 19 since its IPO (initial public offer) date in July 2018.
What started last year with Constellation Brands (STZ) getting involved with the likes of Canopy Growth (CGC) has sparked a firestorm of additional interest from other companies. Furthermore, it has been reported that alcohol company, Diageo (DEO) is showing interest and speaking with 3 other cannabis companies for a potential entry into the space. Integrated Cannabis Company is trading nearly 100% higher than it was a month ago.
WKN: A1C4WM), today announced that it has completed its previously announced distribution of Australis shares and warrants (the "Distribution"). In accordance with the terms of the Distribution, eligible Aurora shareholders were paid one unit of Australis for every 34 Aurora shares outstanding as at August 24, 2018 (the "Record Date). Each unit consists of one common share and one share purchase warrant of Australis.
LAS VEGAS , Sept. 19, 2018 /CNW/ - Australis Capital Inc. (CSE:AUSA) ("Australis"), an emerging investment company primarily focused on the U.S. cannabis industry, announced today the commencement of trading on the Canadian Stock Exchange (CSE) under the ticker "AUSA". This is immediately following the completion of the distribution of common shares and warrants of Australis by Aurora Cannabis (ACB.TO) to its shareholders. "The Australis team is excited to begin trading today and grateful to our friends at Aurora Cannabis as the genesis to what will be a compelling and complimentary US mandate," stated Scott Dowty , Chief Executive Officer of Australis.
Cannabis stocks were mostly higher again, led by Tilray Inc., which rallied sharply on news that the U.S. Drug Enforcement Administration has approved its plan to import a marijuana product and test its efficacy in treating a neurological disorder that affects millions of Americans.
On September 17, BNN Bloomberg reported that Coca-Cola was in talks with Aurora Cannabis (ACB)(ACBFF) to develop a CBD-based (cannabidiol) recovery drink to ease pain, inflammation, and cramping. As a result of this report, the investment community saw a major company taking interest in the marijuana industry, which further underscores the seriousness of the cannabis sector.
Investing.com - Cannabis stocks were off to the races again midday after a regulatory announcement, while consumer staples were hit by a double whammy of trade tensions and weak earnings.
WKN: A1C4WM) today announced it, and its wholly-owned subsidiary MedReleaf, have entered into additional supply arrangements with a number of provinces across Canada to supply a broad range of dried flower and higher margin products, such as pre-rolls, oils and capsules. In addition to supplying adult-consumer use markets in British Columbia , Alberta , Ontario , Quebec and Nova Scotia , the Company is pleased to advise of arrangements with Yukon , Manitoba , Prince Edward Island and Newfoundland and Labrador . The Aurora and MedReleaf brands are expected to have a strong presence across Canada , positioning the Company well for rapid growth in the upcoming adult use market.
Aurora Cannabis Inc. said Tuesday, in response to a regulator's request for comment regarding media reports, that it currently had "no agreement, understanding or arrangement" with respect to a partnership with a beverage company. The stock rallied 5.3% in morning trade. On Monday, the stock soared 18% after a report that Coca-Cola Co. had been in talks with the company. Coke had declined to comment, but confirmed it was closely watching the growth of non-psychoactive CBD as an ingredient in beverages. On Tuesday, Aurora said its policy is not to comment on speculative media reports, but the Investment Industry Regulatory Organization of Canada (IIROC) requested a comment. Aurora's U.S.-listed shares have run up 18% over the past three months, while Coke shares have gained 6.1% and the Dow Jones Industrial Average has tacked on 4.6%.
(Reuters) - Aurora Cannabis Inc (ACB.TO) said on Tuesday it had not partnered with any beverage company, responding to a media report that Coca-Cola Co (KO.N) was in talks with the Canadian weed producer ...
Aurora Cannabis Responds to Media Reports Concerning Rumoured Partnership with Beverage Companies
CORAL GABLES, FL / ACCESSWIRE / September 18, 2018 / Cannabis stocks continue to soar as the market prepares for October 17 and the deadline for legal recreational marijuana sales in Canada. This week it was announced that Coca-Cola (KO) could be ready to throw its hat into the ring with a CBD-based beverage. Integrated Cannabis Company is trading 90% higher than it was a month ago today.
Earlier in this series, we discussed a recent development in which Coca-Cola (KO) was reported to be in talks with Aurora Cannabis (ACB) (ACBFF) to develop a cannabis-infused drink (MJ). The planned legalization of recreational cannabis in Canada is presenting a new market for non-cannabis players to explore. Thus, it is no surprise to see that Canopy Growth (CGC) (WEED) and HEXO (HEXO) have both pursued deals with alcoholic beverage companies.
On September 17, BNN Bloomberg reported that Aurora Cannabis (ACB) (ACBFF) and Coca-Cola (KO) are in “serious talks” to develop cannabis-infused beverages. Coca-Cola joins alcoholic beverage makers Constellation Brands (STZ) and Molson Coors (TAP), which have already formed partnerships with major Canadian cannabis companies Canopy Growth (WEED) (CGC) and HEXO (HEXO), respectively.
Trump Adds $267B Tariff Insult to $200B Tariff Injury Not only will the Trump Administration slap tariffs on $200 billion in Chinese goods by next week, or so is being announced on every scrap of financial media this morning, but the tariff rate will be doubled in 2019. This puts the total amount of goods […] The post Market Morning: Trump Tariff Tantrum, Buybacks Booming, Moon to Pyongyang, Cannabis Coke appeared first on Market Exclusive.
Coca-Cola announced its interest in a statement on Monday, responding to a report from BNN Bloomberg that said it was in talks with Canada's Aurora Cannabis Inc (ACB.TO) to develop drinks infused with cannabidiol (CBD), the non-psychoactive chemical found in marijuana. Coke would join a rush by major alcohol makers and a cigarette company to test the cannabis market and find partners ahead of the Oct. 17 launch of legal recreational marijuana in Canada. Coke and Aurora, in separate statements, each said they were interested in cannabidiol-infused beverages but would not comment on any specifics or talks.
WKN: A1C4WM) and Australis Capital Inc. ("Australis") today announced the common shares and warrants (together the "Units") of Australis are expected to commence trading on the Canadian Securities Exchange (the "CSE") under the trading symbol "AUSA" at the opening of trading on September 19, 2018 immediately following the completion of the distribution of Units by Aurora to its shareholders. To date, the medical use of cannabis is legal in 31 states, the District of Columbia and the territories of Guam and Puerto Rico .